Introduction {#s1}
============

Cornelia de Lange Syndrome (CdLS; OMIM\# 1227470, 300590, 610759, 614701, and 300882) is a heterogeneous disorder in relation to both patients\' phenotype and genotype ([@B1], [@B2]). Alterations in genes encoding subunits or regulators of the cohesin complex, especially those in *NIPBL*, are detected in the majority of CdLS patients. The basic function of the cohesin complex is to control sister chromatids separation during mitosis and meiosis ([@B3]). However, abnormal segregation of chromosomes is not observed in the patient\'s cell lines ([@B4]) and cell cycle disorders are not observed in patients with CdLS. More recent studies indicate the involvement of the cohesin complex in other chromatin-related processes, namely in mediating sister chromatid cohesion, chromatin remodeling, transcriptional regulation, and DNA double-strand break repair ([@B5]). Current data suggest that these functions of the complex may be impaired in a group of CdLS patients.

Interestingly, alterations in genes, such as *ATRX, KMT2A*, and *TAF6*, involved in the epigenetic modification, chromatin remodeling, and transcriptional regulation pathways are responsible for CdLS-like phenotypes ([@B6]). *ATRX* encodes a helicase which regulates the transcription of downstream genes and modifies chromatin structure. *KMT2A* encodes a histone H3 lysine 4 (H3K4) methyltransferase that regulates chromatin-mediated transcription. TAF6 is a component of transcription factor IID (TFIID), which consists of TATA-binding protein (TBP) and 12--14 TBP-associated factors (TAFs) which promote transcriptional initiation. Pathogenic variants in these genes can alter the expression of different genes and lead to abnormalities in multiple body systems, such as those observed in CdLS patients.

It is accepted that mosaic variants in *NIPBL* are frequent in CdLS patients ([@B7]). This type of genetic alterations can lead to the different expression of symptoms among patients. Moreover, only very sensitive techniques can allow detecting this specific type of molecular changes.

In this study, comprehensive mutational analysis was performed to determine the prevalence and spectrum of germline and mosaic alterations in genes encoding subunits and regulators of the cohesin complex and three transcriptional regulators in a group of Polish patients with CdLS. Additionally, the impact of intronic variants on mRNA splicing was studied.

Materials and Methods {#s2}
=====================

Human Subjects and Sample Collection
------------------------------------

A total of 69 CdLS individuals were enrolled in the study, where 39 were females (56,5%), and 30 were males (43,5%). In all patients, CdLS was diagnosed and divided into two groups based on the phenotype according to accepted criteria ([@B8], [@B9]). The first group composed of 33 (47,8%) individuals defined as presenting a classic CdLS phenotype. The second group consisted of 36 (52,2%) individuals with mild CdLS. Of the 39 females, 18 (46,2%) individuals presented the classic phenotype and 21 (53,8%) the mild phenotype. Of the 30 males, 15 (50%) individuals presented classic phenotype and 15 (50%) mild phenotype. To note, 15 previously *NIPBL*-negative patients were included in the study ([@B10]).

DNA was successfully extracted from peripheral blood samples of 68 (98,6%) individuals. In addition, buccal swabs were collected from 21 (30,5%) individuals. To confirm a pathogenic status of detected intronic variants, RNA was extracted from peripheral blood samples of 7 (10,1%) individuals. Finally, familial cosegregation was performed in 31 patients\' relatives.

The study was approved by the local ethics committee at the Medical University of Gdansk. Parents gave written informed consent for molecular genetic testing of their children.

DNA Isolation and Mutational Analysis
-------------------------------------

Genomic DNA was isolated from peripheral blood lymphocytes and oral mucosa epithelial cells using Genomic DNA from blood and Genomic DNA from tissue kits (Macherey-Nagel) according to the manufacturer\'s protocols.

Mutational analysis was performed using NimbleGen Seqcap EZ HyperCap (Roche Diagnostics) and MiSeq (Illumina). In targeted gene-panel, all genes involved in the cohesin complex were selected. Targeted gene-panel was designed to cover entire coding sequences and 25 bp of flanking introns of *NIPBL, SMC1A, SMC3, RAD21, HDAC8, STAG1, SGOL1, PDS5A, PTTG1, TAF6, ESCO2, WAPAL, CDCA5, KMT2A, DDX11, ESPL1, PDS5B, PLK1, AURKB, ESCO1, MAU2, ATRX, STAG2*, and *RECQL4* genes.

Bioinformatics analysis was performed using IGV (Broad Institute), SeqNext (JSI Medical Systems), and Alamut (Interactive Biosoftware) software. The nomenclature of the alterations was based on the mRNA sequence ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}) according to the recommendations of the Human Genome Variety Society ([@B11]). Variants were classified based on the American College of Medical Genetics\' (ACMG) recommendations ([@B12]).

In addition, screening for large rearrangements in *NIPBL* was performed using Multiplex Ligation-dependent Probe Amplification technique (P141 and P142, MRC Holland). PCR fragments were analyzed using the 3100 Series Genetic Analyzer (Thermo Fisher Scientific). Data were analyzed using Coffalyser.Net software (MRC Holland).

Detected pathogenic or potentially pathogenic variants were confirmed by independent PCR reactions followed by bidirectional Sanger sequencing. All primer sequences and annealing temperatures are presented in [Supplementary Table 2](#SM1){ref-type="supplementary-material"}. Electropherograms were analyzed with Sequencher v.10 DNA Software (Gene Codes).

To analyze the effect of detected variants on mRNA splicing, additional blood samples were collected. RNA was extracted using Tempus Spin RNA Isolation Reagent Kit (Thermo Fisher Scientific), and iScript cDNA Synthesis Kit (Bio-Rad) was applied for cDNA synthesis. PCR products were excised from agarose gel and bidirectionally sequenced. For two individuals (CdLS24 and CdLS62), excised PCR products were cloned into a pGEM-T Easy Vector System (Promega) followed by DNA isolation (Plasmid Mini, A&A Biotechnology) and Sanger sequencing. Electropherograms were analyzed with Sequencher v.10 DNA Software (Gene Codes).

Results {#s3}
=======

In total, 69 patients were enrolled to the study. DNA extraction from blood samples was successful for 68 individuals (98,6%) while MLPA and deep (NGS) sequencing analysis was performed in 66 (95,7%) and 67 (97,1%) patients, respectively. Large rearrangements of *NIPBL* were not identified in the studied group. However, pathogenic and potentially pathogenic germline substitutions (*n* = 8; 11,6%), duplications (*n* = 4; 5,8%), and deletions (*n* = 2; 2,9%) of *NIPBL* were detected in 14 (20,3%) individuals. Moreover, four germline variants were found in *SMC1A* (*n* = 2; 2,9%) and in *HDAC8* (*n* = 2; 2,9%). In general, germline variants were detected in 18 (26,1%) patients.

Only 13 (18,8%) buccal swabs were suitable for deep (NGS) sequencing. In one individual (CdLS33), DNA isolated from buccal swabs was the only available material for the molecular testing. In our cohort, mosaic variants were identified in four (30,8%; 4/13) patients negative for germline alterations. Three (23%; 3/13) mosaic substitutions were detected in *NIPBL* and one (7%; 1/13) in *KMT2A* ([Figures 1](#F1){ref-type="fig"}, [2A](#F2){ref-type="fig"}). In one patient (CdLS45), c.5440C\>T (p.Arg1814Ter) *NIPBL* variant was detected in 20% (90/452) of reads in DNA extracted from the buccal swab sample. This genetic variant was not detected in the blood sample. In another patient (CdLS33), substitution c.6206T\>A (p.Ile2069Asn) in *NIPBL* was found in 21% (34/159) of reads of the buccal swab sample. Unfortunately, the blood sample of this patient was not available for the study. In the patient CdLS02M, substitution (c.869-2A\>G, p.Gly290_Lys498del) was detected in 23% (251/1115) and 51% (74/148) of reads in DNA extracted from blood and buccal swab samples, respectively ([@B13]). Finally, a novel intronic and mosaic variant of *KMT2A* (c.4012+1G\>A) was found in 48% (349/823) of reads of DNA extracted from buccal swab sample of patient CdLS09. This variant was not detected in a blood sample of the patient.

![The analysis for the characterization of three mosaic variants. **(A)** NGS analysis and Sanger sequencing chromatograms of gDNA from blood and buccal swab samples of CdLS45 patient (NIPBL:c.5440C\>T). **(B)** NGS analysis and Sanger sequencing chromatograms of gDNA from buccal swab samples of CdLS33 patient (NIPBL:c.6206T\>A). Sanger sequencing chromatograms of gDNA of WT sample. **(C)** NGS analysis and Sanger sequencing chromatograms of gDNA from blood and buccal swab samples of CdLS09 patient (KMT2A:c.4012+1G\>A). Dotted lines in the IGV software and the bluish shading in the chromatograms mark the position if the variants.](fped-07-00203-g0001){#F1}

![The analysis for the characterization of the splicing variants. **(A)** Analysis of patients CdLS02 and CdLS02M (NIPBL:c.896-2A\>G). (A1) NGS analysis of DNA from the mother\'s blood samples (CdLS02M) and the son (CdLS02), on IGV software. (A2) Chromatograms showing the segregation analyses of gDNA Sanger sequencing. The bluish shading in the chromatograms marks the position of the variant. (A3) Chromatograms showing cDNA Sanger sequencing analysis of the mother (CdLS02M) and the son (CdLS02) showing loss of exon 9 in mRNA sequence. The outcomes of alternations splicing of NIPBL protein alignment of the patients with marked in-frame deletion of exon 9 and loss of Gln-rich domain. **(B)** Analysis of patients CdLS24 (NIPBL:c.6954+3A\>C). (B1) Chromatograms showing the segregation analyses of gDNA Sanger sequencing (B2) Chromatograms showing cDNA Sanger sequencing analysis of wild-type and patient (after cloning in the pGEM --T Easy Vector system) showing loss of exon 40 in mRNA sequence. (B3) The outcomes of alternations splicing with loss of exon 40. NIPBL protein alignment exhibits protein truncation and loss of H5 domain. **(C)** Analysis of the patient CdLS (NIPBL:c.5862+1delC). (C1) Chromatograms showing the segregation analyses of gDNA Sanger sequencing. (C2) Chromatograms showing cDNA Sanger sequencing analysis of wild-type and patient (after cloning in the pGEM --T Easy Vector system) showing in-frame insertion of 40 nucleotides of intron 32-33. (C3) The outcomes of alternations splicing with the insertion of 40 nucleotides of intron 32-33. NIPBL protein alignment exhibits protein truncation and loss of H3, H4, and H5 domains.](fped-07-00203-g0002){#F2}

RNA was extracted from blood samples of seven (10,1%) individuals. In four cases, cDNA analysis confirmed that detected variants have an impact on RNA, splicing and alter sequences of encoded proteins ([Figure 2](#F2){ref-type="fig"}). The c.869-2A\>G *NIPBL* substitution identified in patients CdLS02 and CdLS02M leads to an in-frame exon 9 skipping (r.869_1495del; p.Gly290_Lys498del). Another *NIPBL* variant (c.6954+3A\>C) found in CdLS24 patient, resulted in exon 40 skipping (r.6764_6954del; p.Ser2255Leufs^\*^20). In the CdLS62 patient, substitution of *NIPBL* c.5862+1delG caused insertion of 40 nucleotides of intron 32 between sequence of exons 32 and 33 (r.5862_5863ins5862+2_5862_41; p.Leu1955Ter). Patients CdLS24 and CdLS62 were previously reported ([@B14]). Pathogenicity, predicted by *in silico* analysis, of the *SMC1A* variant (c.1114-3_1114-2delCA), detected in patient CdLS29 was not confirmed by mRNA analysis. This variant was re-classified as benign.

Finally, familial cosegregation analysis was performed in 14 (20,3%) individuals. Only in one case (CdLS02), a *NIPBL* pathogenic variant was detected in the patient and his mother ([@B13]).

To summarize, both germline and mosaic variants were found in 22/69 (31,9%) patients. All identified variants are presented in [Table 1](#T1){ref-type="table"} and [Figure 3](#F3){ref-type="fig"}.

###### 

Pathogenic and likely pathogenic variants detected in the studied group of 69 patients with Cornelia de Lange Syndrome.

  **No**.       **Case no**.                              **Gender (M/F)**   **Phenotype**   **Exon/intron**   **Variant in corresponding cDNA**   **Predicted effect**                                                                      **Classification**   **Coverage \[blood sample (%)\]/\[buccal swab sample (%)\]**   **Sanger sequencing**          
  ------------- ----------------------------------------- ------------------ --------------- ----------------- ----------------------------------- ----------------------------------------------------------------------------------------- -------------------- -------------------------------------------------------------- ------------------------------ ----
  ***NIPBL***                                                                                                                                                                                                                                                                                                                                                   
  1             CdLS02                                    M                  Classic         8                 c.869-2A\>G                         r.\[869_1495del\];\[869_1495 = \] p.(Gly290_Lys498del)                                    Pathogenic           \[522/1132(46%)\]/\[ND\]                                       c.\[869-2A\>G\];\[869-2 = \]   WT
  2             CdLS02M                                   F                  Mild            8                 c.869-2A\>G                         r.\[869_1495del\];\[869_1495 = \] p.(Gly290_Lys498del)                                    Pathogenic           \[251/1115(23%)\]/\[76/148(51%)\]                              ND                             ND
  3             CdLS03                                    F                  Mild            29                c.5507G\>A                          r.\[5507g\>a\];\[5507 = \] p.(Gly1836Asp)                                                 Likely pathogenic    \[105/221(48%)\]/\[ND\]                                        WT                             WT
  4             CdLS04                                    M                  Classic         26                c.5167C\>T                          p.(Arg1723Ter)                                                                            Pathogenic           \[153/281(54%)\]/\[ND\]                                        ND                             ND
  5             CdLS11                                    M                  Classic         17                c.3938C\>A                          r.\[3938c\>a\];\[3938 = \] p.(Thr1313Lys)                                                 Likely pathogenic    \[133/286(47%)\]/\[ND\]                                        WT                             WT
  6             CdLS22                                    F                  Classic         12                c.3439C\>T                          p.(Arg1147Ter)                                                                            Pathogenic           \[145/314(46%)\]/\[ND\]                                        WT                             WT
  7             CdLS24                                    M                  Classic         40                c.6954+3A\>C                        r.\[6764_6954del\];\[6764_6954 = \] p.(Ser2255Leufs[^\*^](#TN1){ref-type="table-fn"}20)   Pathogenic           \[98/209(47%)\]/\[ND\]                                         WT                             WT
  8             CdLS33                                    F                  Classic         35                c.6206T\>A                          p.(Ile2069Asn)                                                                            Likely pathogenic    \[ND\]/\[34/159(21%)\]                                         WT                             WT
  9             CdLS42                                    F                  Classic         17                c.4009dup                           p.(Ile1337Asnfs[^\*^](#TN1){ref-type="table-fn"}5)                                        Pathogenic           \[122/257(47%)\]/\[ND\]                                        WT                             WT
  10            CdLS45                                    F                  Classic         29                c.5440C\>T                          p.(Arg1814Ter)                                                                            Pathogenic           \[WT\]/\[90/452(20%)\]                                         ND                             ND
  11            CdLS53                                    F                  Classic         10                c.2252dup                           p.(Asn751Lysfs[^\*^](#TN1){ref-type="table-fn"}2)                                         Pathogenic           \[132/324(41%)\]/\[ND\]                                        WT                             WT
  12            CdLS54                                    M                  Classic         10                c.2635G\>T                          p.(Glu879Ter)                                                                             Pathogenic           \[160/320(50%)\]/\[ND\]                                        ND                             ND
  13            CdLS55[^\*^](#TN1){ref-type="table-fn"}   F                  Classic         36                c.6266_6277dup                      p.(Val2089_Leu2092dup)                                                                    Likely pathogenic    \[7/16(44%)\]/\[ND\]                                           WT                             WT
  14            CdLS58                                    F                  Classic         42                c.7141G\>T                          p.(Gly2381Cys)                                                                            Likely pathogenic    \[107/258(41%)\]/\[ND\]                                        ND                             ND
  15            CdLS62                                    F                  Classic         32                c.5862+1delG                        r.\[5862_5863ins5862+2_5862+41\];\[5862_5863 = \] p.(Leu1955Ter)                          Pathogenic           \[78/165(47%)\]/\[ND\]                                         WT                             WT
  16            CdLS63                                    M                  Mild            10                c.2479_2480delAG                    p.(Arg827Glyfs[^\*^](#TN1){ref-type="table-fn"}2)                                         Pathogenic           \[113/235(48%)\]/\[ND\]                                        WT                             WT
  17            CdLS68                                    F                  Mild            47                c.8287dup                           p.(Val2763Glyfs[^\*^](#TN1){ref-type="table-fn"}5)                                        Pathogenic           \[509/1085(47%)\]/\[ND\]                                       WT                             WT
  ***HDAC8***                                                                                                                                                                                                                                                                                                                                                   
  17            CdLS21                                    F                  Classic         10                c.1081C\>T                          p.(Arg361Ter)                                                                             Pathogenic           \[135/271(50%)\]/\[ND\]                                        WT                             WT
  19            CdLS65                                    F                  Mild            6                 c.562G\>A                           p.(Ala188Thr)                                                                             Pathogenic           \[463/966(48%)\]/\[ND\]                                        WT                             WT
                SMC1A                                                                                                                                                                                                                                                                                                                                           
  20            CdLS05                                    F                  Mild            10                c.1714C\>T                          p.(Pro572Ser)                                                                             Likely pathogenic    \[211/427(49%)\]/\[ND\]                                        ND                             ND
  21            CdLS59                                    F                  Classic         5                 c.802_804delAAG                     p.(Lys268del)                                                                             Likely pathogenic    \[153/318(48%)\]/\[ND\]                                        ND                             ND
  ***KMT2A***                                                                                                                                                                                                                                                                                                                                                   
  22            CdLS09                                    M                  Mild            7                 c.4012+1G\>A                        p.?                                                                                       Pathogenic           \[WT\]/\[392/823(48%)\]                                        ND                             ND

Gender: M, male; F, female. ND, no data; WT, wild-type in tested fragments;

*, TruSightOne*.

![The spectrum of the pathogenic or likely pathogenic variants identified in tested genes. Each variant is unique for one patient. The figure was prepared using the ProteinPaint application ([@B15]).](fped-07-00203-g0003){#F3}

Discussion {#s4}
==========

Overall, pathogenic and potentially pathogenic variants were found in 22 (31,9%) individuals. Of those, 18 (26,1%) alterations were germline while four (5,8%) were mosaic. No large rearrangements of the *NIPBL* were identified in the patients analyzed. The frequency of alterations detected in this study was lower compared to the previous reports (31,9% vs. 60--80%) ([@B2], [@B16]--[@B18]). This low rate of detected alterations can be explained by selection bias since 15 previously *NIPBL*-negative patients were included in the study ([@B10]).

It is accepted that genetic variants are more frequently detected in CdLS patients with classic phenotype than in those with a mild phenotype. Indeed, in our studied group of patients, pathogenic and likely pathogenic variants were found in 45,5% (15/33) individuals with classic phenotype and only in 19,4% (7/36) patients with mild CdLS phenotype. The mutation detection rate among patients with classic phenotype is closer to the data reported in the literature (48,5% vs. 60--80%). Therefore, we can speculate that some patients with a mild phenotype may be diagnosed with a genetic syndrome phenotypically similar to CdLS but with a distinct molecular basis.

In CdLS patients negative for germline mutations, mosaic alterations can be detected. Due to the high sensitivity of the method, NGS seems to be the most appropriate technique to identify such variants ([@B17], [@B19]). To date, several patients with mosaic variants in CdLS-related genes have been reported ([@B17], [@B20], [@B21]). In a group of 44 patients, Huisman et al. detected mosaic variants in *NIPBL* in 10 individuals which accounts for 23% of all identified alterations ([@B7]). In the current study, mosaic variants in *NIPBL* have been identified in three out of 17 *NIPBL*-positive patients (17,6%). Two of them had classic and one mild phenotype of CdLS.

Among other tested genes, a mosaic variant was detected only in one patient with mild CdLS phenotype. It was a novel, intronic c.4012+1G\>A variant in *KMT2A*. This patient demonstrated CdLS--like phenotype with the pre and postnatal microsomy, some dysmorphic features: long eyelashes, low set ears, thin lips, high arched palate, small hands, and feet with V finger clinodactyly, hirsutism with the excessive hair growth near sacrum, mild developmental delay with autistic-like behavior and speech impairment and feeding difficulties. Parents did not agree for the publication of the photography. *In silico* analysis confirmed a pathogenic character of the identified variant since a change of splice-donor site results in an aberrant transcript. Unfortunately, no further sample of this patient was available for RNA studies. Nevertheless, germline *KMT2A* variant (c.2233C\>T, p.Arg745Ter) has been previously described in a patient with an overlapping phenotype of CdLS and Wiedemann-Steiner syndrome ([@B6]). *KMT2A* pathogenic variants have been suggested to contribute to the CdLS-like phenotypic spectrum ([@B6]). To our knowledge, our patient is the first case of mild CdLS phenotype, and an intronic mosaic variant in the *KMT2A* gene.

Based on the previous study, approximately 20% of *NIPBL* variants are located within intron sequences ([@B19]). In this study, three splice site variants have been identified in the *NIPBL* gene in four patients, three with classic CdLS and one with a mild phenotype (mosaic splice site variant). RNA analysis confirmed the pathogenic impact of all variants on the splicing process. In contrast, a splicing variant c.1114-3_1114-2delCA detected in a conserved region of the *SMC1A* gene did not result in an aberrant transcript (patient CdLS29). The actual sequence c.1114-5_1114-4 is identical to the deleted one; therefore splice-acceptor site was not altered nor changed its position. Based on these data, the detected c.1114-3_1114-2delCA variant was re-classified as benign. Splice variants appear to occur more often in patients with a more severe phenotype ([@B22]). Nonetheless, few family cases with splice variants and mild phenotype have been reported ([@B23]). However, based on our data, such variants in a mosaic stage can also be detected in CdLS patients with a mild phenotype. In our cohort, we were able to identify germline splice variant in the son (CdLS02) of an affected patient (CdLS02M) diagnosed with a mosaic alteration and mild phenotype ([@B13]).

In summary, pathogenic variants in selected genes were identified in 22 (31,9%) of 69 CdLS patients. These results indicate that in patients with CdLS, deep (NGS) sequencing techniques should be applied in order to detect a molecular background of the disease. Molecular testing of CdLS patients should allow detecting the presence of mosaic variants, which can be identified in a significant number of individuals. Furthermore, this study showed that simple transcript analysis could be useful to classify pathogenicity of detected intronic variants.

Conclusion {#s5}
==========

Next Generation Sequencing methods should be applied to perform molecular testing of patients with CdLS/CdLS-like phenotypes in order to increase the detection rate of all possible genetic variants, including mosaic and splice site variants, which can be detected in this group of individuals.
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